By activating GLP-1 receptors, semaglutide helps: Stimulate insulin production when blood sugar is high Reduce glucagon secretion, which further lowers blood sugar Slow down digestion, promoting a feeling of fullness Decrease appetite by acting on brain centers controlling hunger The FDA has approved Ozempic for the treatment of type 2 diabetes, while Wegovy, a higher-dose formulation of semaglutide, is specifically approved for chronic weight management in adults with obesity or overweight with at least one weight-related comorbidity
Other Common Side Effects of Ozempic Individuals taking Ozempic may encounter a range of common side effects that should be noted, including those associated with gastrointestinal distress, such as nausea, vomiting, and stomach pain
When combined with medical guidance and lifestyle support, GLP-1 therapy can promote sustainable weight loss and improved metabolic function over time
Preventing Hyperglycemia Hyperglycemia is a common occurrence in hospitalized patients, particularly those admitted for the illness that led to hospitalization